Bies Robert R, Bigos Kristin L, Pollock Bruce G
Department of Pharmaceutical Sciences, 805 Salk Hall, University of Pittsburgh, Pittsburgh, PA 15213, USA.
J Gend Specif Med. 2003;6(3):12-20.
The paucity of research on gender-specific differences related to antidepressants is a significant public health deficiency and represents an understudied and necessary research area. The current data suggest that the pharmacokinetics of antidepressant drugs can be substantially different between men and women as a result of differences in both the metabolizing enzymes and the expression of P-glycoprotein MDR1. The data suggest that different pharmacodynamic responses are observed between premenopausal women and men. Women are more likely to respond better to an MAOI antidepressant compared to men. In addition, men respond better to TCAs than women in this age group, but differences diminish after menopause. Given the evidence of distinct gender-specific differences, it is critical that these differences be addressed more widely in research evaluating the administration of antidepressants in women.
与抗抑郁药相关的性别特异性差异研究匮乏，这是一个重大的公共卫生缺陷，代表了一个研究不足但很有必要的研究领域。目前的数据表明，由于代谢酶和P-糖蛋白MDR1表达的差异，抗抑郁药物在男性和女性体内的药代动力学可能有很大不同。数据显示，绝经前女性和男性之间观察到不同的药效学反应。与男性相比，女性对单胺氧化酶抑制剂抗抑郁药的反应可能更好。此外，在这个年龄组中，男性对三环类抗抑郁药的反应比女性好，但绝经后差异减小。鉴于存在明显的性别特异性差异的证据，在评估女性抗抑郁药给药的研究中更广泛地探讨这些差异至关重要。
